In glioblastoma (GBM) models, RSL3 activates NF‐κB signaling through GPX4 inhibition, subsequently suppressing ATF4/xCT system expression to exacerbate LPO [195].The application of NF‐κB inhibitor BAY 11‐7082 significantly attenuates the antitumor efficacy of RSL3 in vivo, highlighting the critical role of this pathway in ferroptosis. This evidence concerns the gene GPX4 and glioblastoma.